BMO keeps USD 47 target for Novo Nordisk stock

Published on 10/08/2026 at 11:41 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

BMO kept its USD 47.00 target on October 7, 2026. Novo Nordisk stock was EUR 33.68 on October 8, 2026, minus 0.97 percent versus EUR 34.01.

Extreme Makroaufnahme kristalliner Insulinstruktur, blaues Polarisationslicht, Wissenschaft — Novo Nordisk A/S (DK0062498333): extreme Makroaufnahme kristalliner Insulinstruktur als wissenschaftliche Visualisierung in blauem Polarisationslicht, Illustration mit AI erstellt.

Novo Nordisk stock (ISIN DK0062498333) was EUR 33.68 at Lang & Schwarz on October 8, 2026 at 11:36 a.m. CEST, down 0.97 percent versus the EUR 34.01 prior close. BMO Capital maintained a USD 47.00 target on October 7, 2026, according to Gekko.

BMO keeps its USD 47 target

The BMO view leaves the rating at Hold and places the analyst action among the latest dated signals tracked for Novo Nordisk. The target is stated in US dollars for the company's New York-listed American depositary receipt, while the reference quote in this article remains the euro price at Lang & Schwarz.

The split between the two currencies matters for comparison: the target cannot be netted against the euro quote as a single percentage. Investors therefore have two separate reference points, with BMO's USD 47.00 target applying to the US-listed instrument and EUR 33.68 representing the German trading perspective.

Second-quarter sales rose 7 percent

Novo Nordisk reported adjusted sales of DKK 78.49 billion for the second quarter of 2026, up 7 percent at constant exchange rates, according to the company's release published through Globenewswire on August 4, 2026. Adjusted operating profit increased 11 percent to DKK 33.39 billion in the same period.

The company also narrowed its full-year 2026 adjusted sales growth outlook to 0 percent to minus 6 percent at constant exchange rates from a previous range of minus 4 percent to minus 12 percent. The comparable adjusted operating profit outlook was also set at 0 percent to minus 6 percent, making volume growth and execution the central financial variables for the remainder of 2026.

November results set the next test

Novo Nordisk's B shares are listed on Nasdaq Copenhagen and its American depositary receipts trade on the New York Stock Exchange, according to the October 2, 2026 company release distributed by Globenewswire. That release also said the FDA review of denecimig remained ongoing because of manufacturing-facility remediation, while the agency had identified no deficiencies in the submitted clinical efficacy or safety data.

Comdirect lists November 4, 2026 as the confirmed date for Novo Nordisk's third-quarter 2026 report. The date gives the market a defined checkpoint for testing the 0 percent to minus 6 percent outlook against the latest operating performance.

Stock trades below its prior close

Novo Nordisk was trading at EUR 33.68 at Lang & Schwarz on October 8, 2026 at 11:36 a.m. CEST, down 0.97 percent versus the EUR 34.01 prior close. The further course of trading is shown by the continuously updated real-time quote of Novo Nordisk stock.